The CPP Consortium Welcomes Biohaven as its Newest Member


The Critical Path for Parkinson’s Consortium is excited to welcome Biohaven as its newest member. Biohaven is a biopharmaceutical company aimed at discovering and developing novel life-changing therapies for people living with neurological and neuropsychiatric diseases by collaborating with leaders in scientific discovery and medicine. CPP is excited to work with Biohaven as one of many new members from around the globe that are advancing new therapies for Parkinson’s and putting the needs of patients first.